Further application of the adefovir model in patients with renal impairment enabled the accurate prediction of the CKD‐induced changes to adefovir plasma exposure, affirming our recommendation [27] to reduce OAT1 activity beyond the decline of GFR in moderate and severe CKD. Here, SLC22A6 is linked to chronic kidney disease.